The companies collaborate to evaluate Replimune’s RP1 (lead oncolytic immunotherapy product candidate) + Incyte’s INCB99280 to initiate the clinical trial in patients with high-risk, resectable CSCC. The trial is expected to initiate in early 2024
Replimune will supply Incyte with RP1 for the study and share equally in the costs of the study. INCB99280, a potent and selective small molecule oral PD-L1 inhibitor showed promising clinical activity and safety in patients with solid tumors
Additionally, INCB99280 is being studied in multiple P-II studies as a monotx. and in combination with other antitumor agents
Ref: Businesswire | Image: Incyte
Related News:- Roche Entered into Master Clinical Trial Collaboration and Supply Agreement with Replimune for RP2/3 Program to Treat Colorectal Cancer and Hepatocellular Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
